Telix Pharmaceuticals Limited (ASX: TLX) has announced a significant development in its journey towards transforming brain cancer diagnostics. The company has opened an Expanded Access Program (EAP) in the United States for TLX101-CDx (Pixclara™1, 18F-floretyrosine or 18F-FET), an investigational PET agent for imaging progressive or recurrent glioma. This move...
Talanx's peers in the German market Munich RE and Allianz have since the COVID19 sell off in February 2020 recovered better than Talanx. Talanx will likely close this gap soon.
Talanx experienced a golden cross a couple of days ago, and with a rising RSI it is likely that Talanx will move towards 37 EUR over the coming weeks.
Long position entered in 32.13
Stop...